LKS Treatment Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027 Segmented By Type (Focal Motor Seizures, Tonic Seizures, Atonic Seizures), By Treatment (Anticonvulsant Drugs, Corticosteroids, Intravenous Immunoglobulins, Surgery, Speech Therapy, Others), By Diagnosis (Electroencephalogram (EEG), MRI, Audiometry, Genetic Testing, Others), By End User (Hospitals & Cli
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationLKS Treatment Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027 Segmented By Type (Focal Motor Seizures, Tonic Seizures, Atonic Seizures), By Treatment (Anticonvulsant Drugs, Corticosteroids, Intravenous Immunoglobulins, Surgery, Speech Therapy, Others), By Diagnosis (Electroencephalogram (EEG), MRI, Audiometry, Genetic Testing, Others), By End User (Hospitals & Cli
Global LKS treatment market is anticipated to grow with an impressive CAGR value in the mentioned forecast years 2023-2027 on the account of increasing instances of genetic disorders like LKS syndrome. The increasing demand for the effective treatment for the speech impairment and enhancing memories of the infected children to overcome the growth challenges is further driving the growth of the global LKS treatment market in the upcoming five years.
Landau-Kleffner syndrome (LKS) is a very rare neurological symptomatic disease that is often experienced in children aged 4-7 years. The syndrome is specifically characterized by the gradual or sudden development of aphasia in the children. The patient is unable to understand as their comprehension ability diminishes, along with severe speech impairment or expression toward language.
Patient suffering from LKS often face recurrent seizures like epilepsy, where libs defy the motor functions and actions are abnormal. The instance of LKS is more evident in male patients as compared to females. Mutations in the GRIN2A gene causes the disease which is an autosomal dominant inheritance. Further studies mention other gene mutations that can be responsible for the syndrome among the children.
Increasing Instances Drive Market Growth
Although Landau-Kleffner syndrome is a rare disorder, the instances of the disease are increasing due to various genetic, environmental, and acquiring factors, thus driving the growth of the global LKS treatment market in the upcoming five years. Surge in the demand for the effective treatment and increasing demand for the therapeutic treatment for the disease further supports the growth of the global LKS treatment market in the next five years.
Also, progressing symptomatic treatment for the speech impairment, verbal auditory agnosia, abnormal epileptiform activity, behavioral disturbances, and overt seizures are also substantiating the growth of the global LKS treatment market in the future five years. Increasing demand for the early diagnosis and effective treatment is also aiding the growth of the global LKS treatment market in the forecast years, until 2027.
Advanced Medicine Drives Market Growth
In 2018, The prevalence rate of autism spectrum disorder among male children in Georgia was 35.2 per 1,000 8-year-olds.
Landau-Kleffner syndrome (LKS) and autism like disease may not claim lives directly but indirectly causes like motor receptor failure, depression, and other related symptoms may cause death among the children as young as 2 to 8 years.
Child Mortality in the first five years of life worldwide in 2019, by regionAfrica>Eastern Mediterranean>Southeast Asia>Americas>Western Pacific>Europe.
Click here to download the sample
Market Segmentation
The global LKS treatment market segmentation is based on type, treatment, diagnosis, end user, regional distribution, and competitional landscape. Based on type, the market is further bifurcated into focal motor seizures, tonic seizures, and atonic seizures. Treatment based market segmentation is fragmented into anticonvulsant drugs, corticosteroids, intravenous immunoglobulins, surgery, speech therapy, and others.
On the basis of diagnosis, the market is segmented into electroencephalogram (EEG), MRI, audiometry, genetic testing, and others. Based on end user, market is further differentiated into hospitals & clinics, ambulatory care centers, and others.
Company Profile
Johnson & Johnson, Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, Abbott Laboratories, Inc., Cipla, Inc., Glenmark Pharmaceuticals Limited, Mankind Pharma Limited, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, are enlisted in a partial list of major market players of the global LKS treatment market.
The existing market players are highly invested in research and product development along with viable service provisions for the consumers. New market entrants may follow similar strategies along with merger and acquisition methods for future brand establishment.
| Attribute | Details |
| Base Year | 2021 |
| Historical Data | 2017 – 2020 |
| Estimated Year | 2022 |
| Forecast Period | 2023 – 2027 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered |
|
| Regional scope | North America; Europe; Asia Pacific; South America; Middle East & Africa |
| Country scope | United States, Mexico, Canada, China, India, Japan, South Korea, Australia, Germany, France, United Kingdom, Spain, Italy, South Africa, UAE, Saudi Arabia, Brazil, Argentina, Colombia, |
| Key companies profiled | Johnson & Johnson, Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, Abbott Laboratories, Inc., Cipla, Inc., Glenmark Pharmaceuticals Limited, Mankind Pharma Limited, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy